Skip to content

David is a partner in the Corporate M&A Group, based in Matheson’s New York office.

David advises on a broad range of public and private company transactions, specialising in equity capital markets deals, public company M&A (hostile and recommended offers), group reorganisations and corporate redomiciliations.

He also advises corporate and individual clients on European securities law, Irish and UK Listing Rules and the Irish Takeover Rules, as well as Irish company law.

 

Experience and Education

  • Advising Smurfit Kappa Group plc on its $25.5 billion merger with WestRock Company to form Smurfit Westrock.
  • Advising Horizon Therapeutics on all aspects of its proposed acquisition by Amgen for aggregate consideration of $28 billion.
  • Advising Smurfit Kappa Group on its €660 million Share Placing.
  • Advising Willis Towers Watson plc on all aspects of its pending $80 billion business combination with Aon plc, to be effected by means of an Irish law scheme of arrangement.
  • Advising Orpea S.A. on all aspects of its acquisition of the TLC group of nursing homes.
  • Advising various issuers and banks on equity capital markets transactions across a broad range of markets (NYSE, NASDAQ, LSE, Euronext Dublin, Euronext Growth, ASX).
  • Advising a number of Irish, NYSE and NASDAQ listed companies on their respective takeovers by way of scheme of arrangement or general offer under the Irish Takeover Rules.
  • Advising a FTSE 100 company on its acquisition by public tender of a 30% minority interest in a listed company.
  • Advising an existing listed company on its US$74 billion merger of equals and concurrent redomiciliation to Ireland.
  • Advising two existing listed companies on their redomiciliations to Ireland via European cross-border merger.
  • Advising a FTSE 100 company on its successful response to unsolicited takeover offers under the Irish Takeover Rules.
  • Advising various issuers on a number of issuances of secured and unsecured debt.
  • Admitted as a solicitor in Ireland
  • University College Dublin, (BCL)
  • University College Dublin, Master of Laws (Commercial)

News and Insights

View All
News
17/07/2025

Matheson Advises Pandox on its c€1.4bn Recommended Cash Offer for Dalata Hotel Group Plc

Read More
Experience Highlight
16/07/2025

Pandox AB, one of Europe’s largest property owners, advised on its c€1.4bn recommended cash offer for Dalata Hotel Group Plc

Read More
Insights
28/05/2025

Irish FDI Screening Regime – Application to The Life Sciences Sector

Read More
Experience Highlight
05/10/2023

Horizon Therapeutics plc on its $28 Billion acquisition by Amgen Inc.

Read More
News
12/09/2023

Matheson Advises Smurfit Kappa on its merger with WestRock Company

Read More
Experience Highlight
11/09/2023

Smurfit Kappa advised on its merger with WestRock Company

Read More
Insights
12/12/2022

Matheson LLP Advises Horizon Therapeutics plc on its Proposed $28 Billion Acquisition by Amgen Inc.

Read More
News
26/04/2022

Matheson Boosts Overseas Expertise in London and New York

Read More
Experience Highlight
10/04/2022

Trinity Biotech plc on a $45 million strategic investment by MiCo

Read More
News
24/02/2022

Matheson ranked as Leading Firm in Chambers Global Guide 2022

Read More

Accolades

David Jones is named Rising Star Partner

Equity Capital Markets: IFLR1000

2024

© 2025 Matheson LLP | All Rights Reserved